A working group of drug companies and patient advocates, led by former HHS chief Tommy Thompson and a former FDA staffer, are urging lawmakers to impose stricter limits on office use drug compounding than those included in a Senate proposal and to require documentation of patients' need for modified FDA-approved drugs, according to compounding policy recommendations floated this week.
quoted from InsideHealthPolicy